Patent ID: 6872550

Claim:
A vaccine effective to immunize a susceptible mammal against Lyme borreliosis infection comprising a) an immunogenic amount of an OspC antigen consisting essentially of SEQ ID NO. 2; an OspC antigen consisting essentially of SEQ ID No. 4; an OspC antigen consisting essentially of SEQ ID No. 8 and an OspC antigen consisting essentially of SEQ ID No. 12, wherein said amount is in the range of 1 to 100 ug per antigen b) an antigen selected from the group consisting of an OspA antigen from B. burgdorteri strain B31, an OspA antigen from B. burgdorferi strain Orth and an OspA antigen from B. burgdorferi H4, and an OspA antigen from B. burgodorferi strain KL11, and c) a physiologically acceptable excipient.